Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Chronic Pruritus of Unknown Origin
NCT05452343Phase 2Unknown
- Sponsor
- Keymed Biosciences
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of stapokibart in chronic pruritus of unknown origin (CPUO), sponsored by Keymed Biosciences. Status: unknown.
02
Drugs
stapokibart
03
Conditions
chronic pruritus of unknown origin (CPUO)
Beyond the preview
Go deeper on NCT05452343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452343.